TY - JOUR
T1 - Perceived cognitive impairment and occupational functioning in prostate cancer survivors
T2 - an exploratory cross-sectional analysis
AU - Pembroke, Lorna
AU - Sherman, Kerry A.
AU - Dhillon, Haryana M.
AU - Francis, Heather
AU - Gillatt, David
AU - Gurney, Howard
PY - 2025/1/15
Y1 - 2025/1/15
N2 - PurposePerceived cancer-related cognitive impairment (CRCI) has been reported in prostate cancer survivors. Little is known about how CRCI impacts occupational functioning in working-aged prostate cancer survivors (PCS). This study aimed to investigate the association between CRCI and occupational functioning in PCS.MethodsData from 51 PCS, who were employed at the time of diagnosis, undergoing hormonal treatments (e.g., androgen deprivation therapy) or 'watchful waiting'/ 'active surveillance', were analysed. An online survey assessed CRCI using the FACT-Cog Perceived Cognitive Impairments (PCI20) subscale, the EORTC-QLQ-30 two-item cognitive functioning scale, and a single 'Yes/No' CRCI item (i.e., were 'changes in thinking (e.g., memory, attention)' experienced as a treatment side effect). PCS also indicated 'Yes/No' to changes to their ability to work, performance of work duties, and decreased work hours. Logistic regression analyses examined the relationship between CRCI measures and occupational outcomes.ResultsOf the 51 PCS, 19 (37%) endorsed experiencing cognitive side effects from treatment. The single 'Yes/No' CRCI question was significantly associated with perceived changes in work ability and ability to perform work duties at the same level. PCI20 and the EORTC-QLQ-30 cognitive functioning scale were not significantly associated with any occupational outcomes.ConclusionPerceived CRCI is associated with adverse changes to occupational functioning and is important to consider when PCS are making plans to return-to-work following treatment.Implications for Cancer SurvivorsProstate cancer survivors may experience cognitive changes, which may impact their work ability.
AB - PurposePerceived cancer-related cognitive impairment (CRCI) has been reported in prostate cancer survivors. Little is known about how CRCI impacts occupational functioning in working-aged prostate cancer survivors (PCS). This study aimed to investigate the association between CRCI and occupational functioning in PCS.MethodsData from 51 PCS, who were employed at the time of diagnosis, undergoing hormonal treatments (e.g., androgen deprivation therapy) or 'watchful waiting'/ 'active surveillance', were analysed. An online survey assessed CRCI using the FACT-Cog Perceived Cognitive Impairments (PCI20) subscale, the EORTC-QLQ-30 two-item cognitive functioning scale, and a single 'Yes/No' CRCI item (i.e., were 'changes in thinking (e.g., memory, attention)' experienced as a treatment side effect). PCS also indicated 'Yes/No' to changes to their ability to work, performance of work duties, and decreased work hours. Logistic regression analyses examined the relationship between CRCI measures and occupational outcomes.ResultsOf the 51 PCS, 19 (37%) endorsed experiencing cognitive side effects from treatment. The single 'Yes/No' CRCI question was significantly associated with perceived changes in work ability and ability to perform work duties at the same level. PCI20 and the EORTC-QLQ-30 cognitive functioning scale were not significantly associated with any occupational outcomes.ConclusionPerceived CRCI is associated with adverse changes to occupational functioning and is important to consider when PCS are making plans to return-to-work following treatment.Implications for Cancer SurvivorsProstate cancer survivors may experience cognitive changes, which may impact their work ability.
KW - cancer-related cognitive impairment
KW - cognitive functions
KW - occupational functioning
KW - prostate cancer
KW - rehabilitation
KW - return to work
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=mq-pure-production&SrcAuth=WosAPI&KeyUT=WOS:001396205000001&DestLinkType=FullRecord&DestApp=WOS_CPL
UR - http://www.scopus.com/inward/record.url?scp=85217267098&partnerID=8YFLogxK
U2 - 10.1007/s11764-025-01743-2
DO - 10.1007/s11764-025-01743-2
M3 - Article
C2 - 39815138
SN - 1932-2259
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
ER -